CA2909994C - Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level - Google Patents

Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level Download PDF

Info

Publication number
CA2909994C
CA2909994C CA2909994A CA2909994A CA2909994C CA 2909994 C CA2909994 C CA 2909994C CA 2909994 A CA2909994 A CA 2909994A CA 2909994 A CA2909994 A CA 2909994A CA 2909994 C CA2909994 C CA 2909994C
Authority
CA
Canada
Prior art keywords
general formula
tamoxifen
derivative
triphenylphosphonium
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2909994A
Other languages
English (en)
French (fr)
Other versions
CA2909994A1 (en
Inventor
Jiri Neuzil
Lukas Werner
Jan Stursa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOTECHNOLOGICKY USTAV AV CR VVI
Smart Brain sro
Springtide Ventures SRO
Original Assignee
Kkcg AG
BIOTECHNOLOGICKY USTAV AV CR VVI
Smart Brain sro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2909994(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ2013308A3/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by Kkcg AG, BIOTECHNOLOGICKY USTAV AV CR VVI, Smart Brain sro filed Critical Kkcg AG
Publication of CA2909994A1 publication Critical patent/CA2909994A1/en
Application granted granted Critical
Publication of CA2909994C publication Critical patent/CA2909994C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
CA2909994A 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level Active CA2909994C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CZ2013-308A CZ2013308A3 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZPV2013-308 2013-04-24
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
CZPV2014-66 2014-01-29
PCT/CZ2014/000035 WO2014173374A1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Publications (2)

Publication Number Publication Date
CA2909994A1 CA2909994A1 (en) 2014-10-30
CA2909994C true CA2909994C (en) 2018-06-26

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2909994A Active CA2909994C (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Country Status (21)

Country Link
US (1) US9896466B2 (https=)
EP (1) EP2989110B1 (https=)
JP (1) JP6375091B2 (https=)
KR (1) KR101764991B1 (https=)
CN (1) CN105452265B (https=)
AU (1) AU2014256546B2 (https=)
CA (1) CA2909994C (https=)
CY (1) CY1120821T1 (https=)
DK (1) DK2989110T3 (https=)
EA (1) EA029881B1 (https=)
ES (1) ES2699099T3 (https=)
GE (2) GEAP201813996A (https=)
HR (1) HRP20181872T1 (https=)
HU (1) HUE042239T2 (https=)
MD (1) MD4626C1 (https=)
NZ (1) NZ713589A (https=)
PL (1) PL2989110T3 (https=)
PT (1) PT2989110T (https=)
SI (1) SI2989110T1 (https=)
UA (1) UA116469C2 (https=)
WO (1) WO2014173374A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016290425A1 (en) * 2015-07-03 2018-01-18 Bayer Cropscience Aktiengesellschaft N-(tetrazole-5-yl)- and N-(triazole-5-yl)aryl carboxamide derivatives with herbicidal action
US10556874B2 (en) * 2015-07-03 2020-02-11 Bayer Cropscience Aktiengesellschaft N-(1,3,4-oxadiazol-2-yl)aryl carboxamide derivatives with herbicidal action
HK1257296A1 (zh) * 2016-07-12 2019-10-18 Accutar Biotechnology Inc. 新的化合物及其用途
WO2018034945A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
RU2020116649A (ru) 2017-10-24 2021-11-30 Лунелла Байотек, Инк. Митофлавосцины: нацеливание на флавин-содержащие ферменты устраняет злокачественные стволовые клетки (cscs) посредством ингибирования митохондриального дыхания
US10980821B2 (en) 2017-11-24 2021-04-20 Lunella Biotech, Inc. Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
US11497759B2 (en) 2017-12-01 2022-11-15 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
EP3728300A4 (en) 2017-12-20 2021-08-11 Lunella Biotech, Inc. TARGETING OF MITOCHONDRIAL FISSION BY MDIVI-1 DERIVATIVES
CA3136811A1 (en) * 2019-04-16 2020-10-22 Lunella Biotech, Inc. Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504522A (ja) * 1990-10-01 1994-05-26 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 高親和性タモキシフェン誘導体とその使用
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
CN1997403A (zh) * 2004-07-13 2007-07-11 奥里迪斯生物医学研究及开发有限责任公司 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途
NZ602579A (en) * 2008-03-14 2013-12-20 Stephen John Ralph Mitochondrially delivered anti-cancer compounds
CA2756820A1 (en) * 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Also Published As

Publication number Publication date
CN105452265A (zh) 2016-03-30
EP2989110B1 (en) 2018-08-08
HUE042239T2 (hu) 2019-06-28
WO2014173374A1 (en) 2014-10-30
CN105452265B (zh) 2017-05-10
MD4626C1 (ro) 2019-11-30
EA201591918A1 (ru) 2016-02-29
JP2016522179A (ja) 2016-07-28
CA2909994A1 (en) 2014-10-30
HK1216317A1 (zh) 2016-11-04
EA029881B1 (ru) 2018-05-31
HRP20181872T1 (hr) 2019-02-08
MD4626B1 (ro) 2019-04-30
US20160075726A1 (en) 2016-03-17
AU2014256546A1 (en) 2015-11-12
SI2989110T1 (sl) 2019-01-31
KR101764991B1 (ko) 2017-08-10
PT2989110T (pt) 2018-11-15
KR20150144756A (ko) 2015-12-28
US9896466B2 (en) 2018-02-20
NZ713589A (en) 2017-12-22
MD20150117A2 (ro) 2016-08-31
PL2989110T3 (pl) 2019-03-29
JP6375091B2 (ja) 2018-08-15
UA116469C2 (uk) 2018-03-26
DK2989110T3 (en) 2018-12-03
CY1120821T1 (el) 2019-12-11
AU2014256546B2 (en) 2017-03-30
EP2989110A1 (en) 2016-03-02
GEAP201813996A (en) 2018-03-12
ES2699099T3 (es) 2019-02-07
GEP20186868B (en) 2018-06-25

Similar Documents

Publication Publication Date Title
CA2909994C (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
Burmaoglu et al. Synthesis, biological evaluation and molecular docking studies of bis-chalcone derivatives as xanthine oxidase inhibitors and anticancer agents
Xu et al. Design, synthesis and biological evaluation of pyridine-chalcone derivatives as novel microtubule-destabilizing agents
Jaouen et al. Ferrocifen type anti cancer drugs
JP2016522179A5 (https=)
CN105669597B (zh) 淀粉状蛋白结合剂
Girgis et al. Synthesis, and QSAR analysis of anti-oncological active spiro-alkaloids
Nosova et al. Enhancing the cytotoxic activity of anticancer PtIV complexes by introduction of lonidamine as an axial ligand
Sun et al. Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR
Mohassab et al. Design and synthesis of new quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases
Yang et al. A novel drug prejudice scaffold-imidazopyridine-conjugate can promote cell death in a colorectal cancer model by binding to β-catenin and suppressing the Wnt signaling pathway
Liu et al. Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl) cyclobutane-1, 1-Dicarboxylate as a leaving ligand
Luo et al. Discovery of 3-(2-aminobenzo [d] thiazol-5-yl) benzamide derivatives as potent anticancer agents via ROR1 inhibition
Vosooghi et al. Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs
AU2016212552B2 (en) Compound containing indoleacetic acid core structure and use thereof
Abdulwahab et al. Anticancer activity of fused quinazoline-quinazolinone: Synthesis, biological evaluations, and computational studies
CZ2013308A3 (cs) Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
JP6423349B2 (ja) Ｎ−置換３，４−ビス（カテコール）ピロール化合物、その調製、及びガンの治療のためのその使用
CZ201466A3 (cs) Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
HK1216317B (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
WO2018145217A1 (en) Human ets-related gene (erg) compounds as therapeutics and methods for their use
Alotaibi Design, synthesis and biological evaluation of novel estradiol-triazole analogs targeting epidermal growth factor receptors in colorectal cancer
Khalaf Alshamari et al. Exploration of Novel 2, 6-Bis (1-Aryl-1, 2, 3-Triazol-4-yl) Pyridine Derivatives: Synthesis, Apoptotic Antiproliferative Evaluation, and In silico Insight as EGFR Inhibitors
WO2025129032A1 (en) Chd1l inhibitors for treating cancer
Thomas Novel Dichloroacetate Prodrugs for Improved Targeting of Breast Cancer Chemotherapeutics

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251006

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260120